The fact that BRAF and KRAS/NRAS are mutually exclusive mutations in CRC supports the hypothesis that BRAF is the main effector of KRAS/NRAS in the MAPK pathway and that both have similar effects on tumorigenesis [48,49]. This evidence concerns the gene BRAF and colorectal carcinoma.